Literature DB >> 35663533

Reactivation of Hepatitis B Virus Among Patients With Cancer Receiving Immunotherapy.

Jessica P Hwang1, Bulent Yilmaz2.   

Abstract

Entities:  

Keywords:  hepatitis B virus; immune checkpoint inhibitors; immunotherapy; reactivation

Year:  2020        PMID： 35663533      PMCID： PMC9153263          DOI： 10.36401/JIPO-20-19

Source DB:  PubMed          Journal:  J Immunother Precis Oncol        ISSN： 2590-017X


× No keyword cloud information.
  16 in total

Review 1.  American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Authors:  Robert P Perrillo; Robert Gish; Yngve T Falck-Ytter
Journal:  Gastroenterology       Date:  2014-10-31       Impact factor: 22.682

2.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

Review 3.  Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.

Authors:  Filipe Martins; Latifyan Sofiya; Gerasimos P Sykiotis; Faiza Lamine; Michel Maillard; Montserrat Fraga; Keyvan Shabafrouz; Camillo Ribi; Anne Cairoli; Yan Guex-Crosier; Thierry Kuntzer; Olivier Michielin; Solange Peters; Georges Coukos; Francois Spertini; John A Thompson; Michel Obeid
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

4.  Safe use of nivolumab in a patient with renal cell carcinoma and hepatitis B.

Authors:  Emre Akar; Halil F Baytekin; Hatice Deniz; Deniz Tural
Journal:  J Oncol Pharm Pract       Date:  2019-10-21       Impact factor: 1.809

5.  Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update.

Authors:  Jessica P Hwang; Mark R Somerfield; Devena E Alston-Johnson; Donna R Cryer; Jordan J Feld; Barnett S Kramer; Anita L Sabichi; Sandra L Wong; Andrew S Artz
Journal:  J Clin Oncol       Date:  2015-05-11       Impact factor: 44.544

6.  PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model.

Authors:  Horng-Tay Tzeng; Hwei-Fang Tsai; Hsiu-Jung Liao; Yi-Jiun Lin; Lieping Chen; Pei-Jer Chen; Ping-Ning Hsu
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

7.  A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B.

Authors:  Anita Pandey; Susan Ezemenari; Maksim Liaukovich; Ivan Richard; Avezbakiyev Boris
Journal:  Case Rep Oncol Med       Date:  2018-10-17

8.  Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

Authors:  Bernhard Scheiner; Martha M Kirstein; Florian Hucke; Fabian Finkelmeier; Kornelius Schulze; Johann von Felden; Sandra Koch; Philipp Schwabl; Jan B Hinrichs; Fredrik Waneck; Oliver Waidmann; Thomas Reiberger; Christian Müller; Wolfgang Sieghart; Michael Trauner; Arndt Weinmann; Henning Wege; Jörg Trojan; Markus Peck-Radosavljevic; Arndt Vogel; Matthias Pinter
Journal:  Aliment Pharmacol Ther       Date:  2019-04-12       Impact factor: 8.171

9.  Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.

Authors:  Neil J Shah; Ghassan Al-Shbool; Matthew Blackburn; Michael Cook; Anas Belouali; Stephen V Liu; Subha Madhavan; Aiwu Ruth He; Michael B Atkins; Geoffrey T Gibney; Chul Kim
Journal:  J Immunother Cancer       Date:  2019-12-17       Impact factor: 13.751

10.  Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.

Authors:  Xuanye Zhang; Yixin Zhou; Chen Chen; Wenfeng Fang; Xiuyu Cai; Xiaoshi Zhang; Ming Zhao; Bei Zhang; Wenqi Jiang; Zuan Lin; Yuxiang Ma; Yunpeng Yang; Yan Huang; Hongyun Zhao; Ruihua Xu; Shaodong Hong; Li Zhang
Journal:  J Immunother Cancer       Date:  2019-11-21       Impact factor: 13.751
View more
  2 in total

1.  The immune system, cancer, and pathogens: It takes three to tango!

Authors:  Joud Hajjar
Journal:  J Immunother Precis Oncol       Date:  2021-05-14

2.  Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy.

Authors:  Xuanye Zhang; Dan Tian; Yue Chen; Chen Chen; Li-Na He; Yixin Zhou; Haifeng Li; Zuan Lin; Tao Chen; Yuhong Wang; Alessandro Russo; Ernest Nadal; Francesco Passiglia; Ross Andrew Soo; Satoshi Watanabe; Teresa Moran; In-Jae Oh; Sha Fu; Shaodong Hong; Li Zhang
Journal:  Transl Lung Cancer Res       Date:  2021-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.